• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cureus . Trend of SARS-Cov-2-Specific IgG Antibody Titers Among COVID-19 Pneumonia Patients: A Nine-Month Follow-Up

tetano

Editor, Senior Moderator
Cureus


. 2023 Jun 23;15(6):e40860.
doi: 10.7759/cureus.40860. eCollection 2023 Jun. Trend of SARS-Cov-2-Specific IgG Antibody Titers Among COVID-19 Pneumonia Patients: A Nine-Month Follow-Up

Manzoor Ahmad[SUP] 1 [/SUP], Mohammad Muttahir Uddin[SUP] 2 [/SUP], Abdul Ahad Wani[SUP] 1 [/SUP], Ishrat Majeed[SUP] 2 [/SUP], Ruquaya Aziz[SUP] 3 [/SUP], Mubarak Naqash[SUP] 4 [/SUP]



Affiliations
Abstract

Introduction Understanding the dynamics of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) spike antibody titers after natural infection is important for understanding immunological memory. This longitudinal study was conducted to assess the trend in serum SARS-CoV-2 IgG spike antibody titers in a cohort of recovered cases up to nine months after SARS infection. Materials and methods We examined the neutralizing antibody response (IgG spike) in serum samples from a cohort of 86 SARS-CoV-2 quantitative polymerase chain reaction (qPCR)-confirmed infection, comprising cases having minor COVID-19 pneumonia and severity, which was determined by CT severity scores. Patients were enrolled in August/September 2020 and serum samples have been processed at one, three, six, and nine months. CT severity scores were rated between 1-25 and antibody titers≥ 1.4 were considered positive. Results The mean anti-SARS-CoV-2-specific IgG antibody titers at one month, three months, six months, and nine months were 22.02 ± 18.36, 14.62 ± 12.61, 8.93 ± 8.10, and 3.86 ± 5.70, respectively. The difference was statistically significant. The seropositivity rates (titer ≥1.4 IU) were 93.02%, 82.56%, 76.74%, and 58.14% at one, three, six, and nine months after infection, respectively. Cases with severe CT severity scores showed significantly higher mean antibody levels at all follow-up visits.

Keywords: coronavirus disease 19 pneumonia; immunological memory; prospective study; reverse-transcription polymerase chain reaction (rt-pcr) test; seropositivity rates; severe acute respiratory syndrome coronavirus 2 specific igg antibody titres; supplemental oxygen.

 
Back
Top Bottom